Our Company

Oncodrone BV (Nijmegen, the Netherlands) was founded in 2013.
The company focuses on developing novel therapeutics for advanced cancer by targeting:

  1. Epithelial-to-Mesenchymal Transition (EMT)
  2. Androgen Receptor (AR) Signaling

Our Team

Team member Oncodrone

Henk Viƫtor
Chief Executive Officer

Team member Oncodrone

Jack Schalken
Chief Scientific Officer

Team member Oncodrone

Johan Tijhuis
non-executive

Team member Oncodrone

Antoine Wellink
Director Drug Development